TCM BIOTECH INTERNATIONAL CORP.
๐น๐ผTaiwan
- Country
- ๐น๐ผTaiwan
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.tcmbio.com
Clinical Trials
6
Active:0
Completed:2
Trial Phases
4 Phases
Phase 1:1
Phase 2:1
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)โข Click on a phase to view related trials
Not Applicable
2 (40.0%)Phase 1
1 (20.0%)Phase 2
1 (20.0%)Phase 3
1 (20.0%)Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women
Not Applicable
Recruiting
- Conditions
- Recurrent Urinary Tract Infections in Women
- Interventions
- Other: Placebo
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- TCM Biotech International Corp.
- Target Recruit Count
- 348
- Registration Number
- NCT07184827
- Locations
- ๐จ๐ณ
Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City, Taiwan
๐จ๐ณKaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
๐จ๐ณTaipei Tzu Chi Hospital, New Taipei City, Taiwan
Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects
Not Applicable
Recruiting
- Conditions
- NAFLD
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- TCM Biotech International Corp.
- Target Recruit Count
- 108
- Registration Number
- NCT05930093
- Locations
- ๐จ๐ณ
National Taiwan University Hospital, Taipei City, Not required for this country, Taiwan
Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence
Completed
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- TCM Biotech International Corp.
- Target Recruit Count
- 207
- Registration Number
- NCT05823584
- Locations
- ๐จ๐ณ
National Taiwan University Hospital, Taipei, Taiwan
A Study of PTX-9908 Injection for Non-resectable HCC with TACE
Phase 1
Recruiting
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: PTX-9908 InjectionDrug: Placebo
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- TCM Biotech International Corp.
- Target Recruit Count
- 50
- Registration Number
- NCT03812874
- Locations
- ๐จ๐ณ
National Taiwan University Hospital, New Taipei City, Taiwan
The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)
Phase 3
Withdrawn
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2013-07-01
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- TCM Biotech International Corp.
- Registration Number
- NCT01890200
- Locations
- ๐จ๐ณ
Peking University People's Hospit, Beijing, Beijing, China
๐จ๐ณChang Gung Memorial Hospital, Taoyuan, Taiwan
- Prev
- 1
- 2
- Next
News
No news found